SUPPORTING INFORMATION

A New Facile Synthesis of 3-Amidoindole Derivatives and Their Evaluation as Potential GSK-3β Inhibitors

Anahit Pews-Davtyan,^a Annegret Tillack,^a Anne-Caroline Schmöle,^b Stefanie Ortinau,^b Moritz J. Frech,^b Arndt Rolfs,^b* and Matthias Beller^a*

^aLeibniz-Institut für Katalyse e.V. an der Universität Rostock, Albert-Einstein-Str. 29a, D-18059 Rostock, Germany. Fax: +49 381 1281 51113; Tel: +49 381 1281 113; E-mail: <u>matthias.beller@catalysis.de</u>

^bAlbrecht-Kossel-Institute for Neuroregeneration, Center for Mental Health Disease, University of Rostock, Gehlsheimerstr. 20, D-18147 Rostock, Germany. Fax: +49 381 494 4699; Tel: +49 381 494 9540; E-mail: <u>arndt.rolfs@med.uni-rostock.de</u>

General Information

All reactions were carried out under argon atmosphere. Reactions were monitored by TLC analysis (pre-coated silica gel plates with fluorescent indicator UV₂₅₄, 0.2 mm) and visualized with 254 nm UV light or iodine. Chemicals were purchased from Aldrich, Fluka, Acros, AlfaAsar, Strem and unless otherwise noted were used without further purification. All compounds were characterized by ¹H NMR, ¹³C NMR, GC-MS, HRMS and IR spectroscopy. ¹H spectra were recorded on Bruker AV 300 and AV 400 spectrometers. ¹³C NMR and ¹⁹F NMR spectra were recorded at 75.5 MHz and 282 MHz respectively. Chemical shifts are reported **only for major rotamer** (short signals on NMR scans belong to minor rotamer) in ppm relative to the center of solvent resonance. Melting points were determined on a digital SMP3 (Stuart). IR spectra were recorded on FT-IR ALPHA (Bruker) with Platinum-ATR (Bruker). EI (70 eV) mass spectra were recorded on Agilent 6890 chromatograph with a 30 m HP5 column. HRMS was performed on MAT 95XP (EI) and Agilent 6210 Time-of-Flight LC/MS (ESI). GC-MS was performed on Agilent 5973 chromatograph Mass Selective Detector. All yields reported refer to isolated yields.

General procedure:

In an Ace-pressure tube to a solution of alkyne derivative **2a-d** (1 mmol) and arylhydrazine derivative **1a-k** (1.5 mmol) in 1,2-dimethoxyethane or toluene (3 mL), zinc bromide or zinc chloride (3 mmol) was added under argon atmosphere. The pressure tube was fitted with a Teflon cap and heated at 110 °C for 20 h (TLC control). After removal of the solvent, the crude product was purified by column chromatography and recrystallized using heptane with ethyl acetate, acetone or dichloromethane.

N-(5-Bromo-2-methyl-1H-indol-3-yl)acetamide (3) from arylhydrazine 1a and alkyne 2a

Where \mathbf{M}_{R} (Figure 1) and \mathbf{M}_{R} (Figure 1) white crystals; **Mp** 232 °C (from CH₂Cl₂/heptane); **R**_f = 0.4 (solvent ethyl acetate/ethanol 20:1); ¹**H** NMR (300 MHz, DMSO-d₆): δ = 2.05 (s, 3H), 2.08 (s, 3H), 7.09 (dd, 1H, J = 3.9, 8.5 Hz), 7.20 (d, 1H, J = 8.5 Hz), 7.41 (d, 1H, J = 1.9 Hz), 9.23 (s, 1H), 11.08 (s, 1H); ¹³**C** NMR (DMSO-d₆): δ = 11.2, 22.7, 110.0, 110.9, 112.6, 119.7, 122.5, 126.5, 131.1, 132.2, 168.5; **GC-MS** (EI, 70 eV): m/z (%) 266 (66) [M⁺], 268 (64.7) [M⁺]; **HRMS** (EI): Calc for C₁₁H₁₁BrN₂O: 266.00493 and 268.00288; found:

266.00472 and 268.00224; FTIR (ATR, cm⁻¹): 3246, 3215, 3191, 3061, 2920, 2732, 1629, 1540, 1423, 1287, 792, 702, 687, 669.

N-(5-Fluoro-2-methyl-1H-indol-3-yl)acetamide (4) from arylhydrazine 1b and alkyne 2a



CI

Yield: 149 mg (72%); white crystals; Mp 180-181 °C (from acetone/heptane); $\mathbf{R}_{\mathbf{f}} = 0.37$ (solvent ethyl acetate/heptane 5:1); ¹H NMR $(300 \text{ MHz}, \text{DMSO-d}_6)$: $\delta = 2.07$ (s, 3H), 2.27 (s, 3H), 6.82 (m, 1H), 6.98 (dd, 1H, J = 2.45, 9.97 Hz), 7.22 (dd, 1H, J = 4.41, 8.74 Hz), 9.21 (s, 1H), 10.95 (s, 1H); ¹³C NMR (DMSO-d₆): $\delta = 11.3$, 22.7, 102.2 (d, J =

23.86 Hz), 107.9 (d, J = 25.91 Hz), 110.7 (d, J = 4.42 Hz), 111.5 (d, J = 9.69 Hz), 125.1 (d, J = 10.09 Hz), 130.1, 131.7, 156.7 (d, J = 230.92 Hz), 168.5; GC-MS (EI, 70 eV): m/z (%) 206 (52) $[M^+]$; ¹⁹**F NMR** (DMSO-d₆): δ = -125.1; **HRMS** (EI): Calc for C₁₁H₁₁ON₂F: 206.08499; found: 206.084715; FTIR (ATR, cm⁻¹): 3241, 3055, 2981, 1926, 1626, 1582, 1532, 1489, 1447, 1430, 1372, 1304, 1190, 1130, 1107, 963, 843, 791, 758, 740, 703, 669.

N-(5-Chloro-2-methyl-1H-indol-3-yl)acetamide (5) from arylhydrazine 1c and alkyne 2a

NHAc 198 mg (89%); white crystals; Mp 213 °C (from Yield: acetone/heptane); $\mathbf{R}_{f} = 0.29$ (solvent ethyl acetate/heptane 4:1); ¹H NMR Me $(300 \text{ MHz}, \text{DMSO-d}_6)$: $\delta = 2.05$ (s, 3H), 2.23 (s, 3H), 6.98 (dd, 1H, J = 2.0, 8.5 Hz), 7.24 (d, 1H, J = 8.7 Hz), 7.26 (d, 1H, $J \sim 1.9$ Hz), 9.23 (s,

1H), 11.06 (s, 1H); ¹³C NMR (DMSO-d₆): $\delta = 11.2, 22.7, 110.2, 112.1, 116.7, 119.9, 122.9, 122.9, 122.9, 120.$ 125.8, 131.3, 131.9, 168.5; GC-MS (EI, 70 eV): m/z (%) 222 (59) [M⁺]; HRMS (EI): Calc for C₁₁H₁₁ON₂Cl: 222.05544; found: 222.05529; **FTIR** (ATR, cm⁻¹): 3218, 3190, 3095, 3064, 2982, 2955, 2922, 2766, 2736, 1629, 1566, 1541, 1425, 1289, 1055, 873, 780, 792, 697, 672.

N-(5-Iodo-2-methyl-1H-indol-3-yl)acetamide (6) from arylhydrazine 1d and alkyne 2a

NHAc Yield: 220 mg (70%); white crystals; Mp 231 °C (dec.) (from acetone/heptane); $\mathbf{R}_{\mathbf{f}} = 0.33$ (solvent ethyl acetate/ethanol 20:1); ¹H ·Me **NMR** (300 MHz, DMSO-d₆): $\delta = 2.04$ (s, 3H), 2.22 (s, 3H), 7.09 (d, 1H, J = 8.5 Hz), 7.24 (dd, 1H, J = 1.75, 8.5 Hz), 7.59 (d, 1H, J = 1.6 Hz), 9.22 (s, 1H), 11.06 (s, 1H); ¹³C NMR (DMSO-d₆): $\delta = 11.3, 22.7, 82.0, 109.6, 113.2, 125.9,$ 127.4, 128.0, 130.7, 132.6, 168.6; MS (EI): m/z (%) 314 (100) [M⁺]; HRMS (EI): Calc for C₁₁H₁₁ON₂I: 313.99106; found: 313.99116; **FTIR** (ATR, cm⁻¹): 3244, 3219, 3085, 3056, 2980, 2916, 2726, 1627, 1566, 1539, 1473, 1420, 1285, 1241, 1010, 799, 793, 749, 698, 677, 665.

N-(2-Methyl-5-(methylsulfonyl)-1H-indol-3-yl)acetamide (7) from arylhydrazine 1e and alkyne 2a

NHAc MeO_2S Me

Yield: 237 mg (89%); yellow crystals; Mp from 230 °C (dec.) (from acetone/heptane); $\mathbf{R}_{f} = 0.45$ (solvent ethyl acetate/ethanol 10:1); ¹H **NMR** (300 MHz, DMSO-d₆): $\delta = 2.08$ (s, 3H), 2.27 (s, 3H), 3.12 (s, 3H), 7.45 (d, 1H, J = 8.52 Hz), 7.53 (dd, 1H, J = 1.75, 8.52 Hz), 7.88 (d, 1H, J = 1.56 Hz), 9.41 (s, 1H), 11.48 (s, 1H); ¹³C NMR (DMSO-d₆): δ = 11.5, 22.8, 44.6, 111.3, 111.8, 117.7, 118.7, 124.1, 130.8, 132.5, 135.6, 168.6; GC-MS (EI): m/z (%) 266 (42) [M⁺]; **HRMS** (EI): Calc for C₁₂H₁₄O₃N₂S: 266.07196; found: 266.07217; **FTIR** (ATR, cm⁻¹): 3353, 3291, 3073, 3016, 2991, 2918, 1645, 1594, 1511, 1303, 1280, 1158, 1133, 1119, 1059, 958,

N-(5-Cyano-2-methyl-1H-indol-3-yl)acetamide (8) from arylhydrazine 1f and alkyne 2a

NC Me

806, 763.

NHAc 171 mg (80%); white crystals; Mp 272 °C (from Yield: acetone/heptane); $\mathbf{R}_{\mathbf{f}} = 0.43$ (solvent ethyl acetate/ethanol 10:1); ¹H

NMR (300 MHz, DMSO-d₆): $\delta = 2.07$ (s, 3H), 2.26 (s, 3H), 7.34 (dd, 1H, J = 1.54, 8.39 Hz), 7.40 (dd, 1H, J = 0.53, 8.39 Hz), 7.72 (d, 1H, J = 0.57 Hz), 9.35 (s, 1H), 11.49 (s, 1H); ¹³C **NMR** (DMSO-d₆): $\delta = 11.3$, 22.7, 100.3, 111.3, 111.9, 120.8, 123.1, 123.2, 124.5, 132.1, 135.3, 168.7; **GC-MS** (EI): m/z (%) 213 (54) [M⁺]; **HRMS** (EI): Calc for C₁₂H₁₁ON₃: 213.08966; found: 213.08999; **FTIR** (ATR, cm⁻¹): 3293, 3236, 3116, 3029, 2920, 2730, 2223, 1628, 1597, 1521, 1476, 1441, 1367, 1310, 1278, 1248, 1197, 1030, 874, 802, 725, 686, 664.

<u>N-(5-Isopropyl-2-methyl-1*H*-indol-3-yl)acetamide (9) from arylhydrazine 1g and alkyne 2a</u>

(Me)₂HC Me Yield: 216 mg (94%); light brown-yellow crystals; **Mp** 171 °C (from acetone/heptane); **R**_f = 0.5 (solvent ethyl acetate/heptane 5:1); ¹H NMR (300 MHz, DMSO-d₆): δ = 1.22 (d, 6H, *J* = 6.92 Hz), 2.05 (s, 3H), 2.20 (s, 3H), 6.89 (dd, 1H, *J* = 1.66, 8.30 Hz), 7.10 (d, 1H, *J* < 0.5 Hz), 7.14

(d, 1H, J = 8.30 Hz), 9.15 (s, 1H), 10.68 (s, 1H); ¹³C NMR (DMSO-d₆): $\delta = 11.4$, 22.7, 24.7, 33.6, 100.1, 110.4, 113.9, 119.2, 124.9, 129.6, 132.2, 138.3, 168.4; GC-MS (EI): m/z (%) 230 (83) [M⁺]; HRMS (EI): Calc for C₁₄H₁₈ON₂: 230.14136; found: 230.14183; FTIR (ATR, cm⁻¹): 3258, 3066, 2965, 2928, 2889, 2869, 2732, 1630, 1544, 1425, 1285, 1244, 804, 696, 677, 662.

<u>N-(5-Bromo-7-fluoro-2-methyl-1*H*-indol-3-yl)acetamide (10) from arylhydrazine 1h and alkyne 2a</u>



Yield: 188 mg (66%); white crystals; Mp 228 °C (from acetone/heptane); $\mathbf{R}_{f} = 0.29$ (solvent ethyl acetate/heptane 4:1); ¹H NMR (400 MHz, Acetone-d₆): $\delta = 2.12$ (s, 3H), 2.31 (s, 3H), 6.96 (dd, 1H, J = 1.59, 10.56 Hz), 7.34 (dd, 1H, $J \sim 0.58$, 1.63 Hz), 8.55 (s, 1H), 10.57 (s, 1H); ¹³C NMR (Acetone-d₆): $\delta = 11.1$, 22.6, 109.2 (d, J = 20.6 Hz),

110.6 (d, J = 8.7 Hz), 112.1, 117.0 (d, J = 3.5 Hz), 121.2 (d, J = 12.8 Hz), 130.7, 133.5, 149.1 (d, J = 251.2 Hz), 169.0; ¹⁹**F NMR** (Acetone-d₆): $\delta = -134.5$; **GC-MS** (EI): m/z (%) 284 (62) [M⁺], 286 (58) [M⁺]; **HRMS** (EI): Calc for C₁₁H₁₀ON₂BrF: 283.99551; found: 283.99542; **FTIR** (ATR, cm⁻¹): 3255, 3159, 3108, 3063, 2985, 2959, 2924, 2871, 2740, 1629, 1573, 1542, 1460, 1443, 1415, 1361, 1289, 1261, 1215, 886, 860, 818, 737, 701, 686.

<u>N-(5,7-Dichloro-2-methyl-1*H*-indol-3-yl)acetamide (11) from arylhydrazine 1i and alkyne 2a</u>



Yield: 198 mg (77%); white crystals; **Mp** 205-207 °C (from acetone/heptane); **R**_f = 0.32 (solvent ethyl acetate/heptane 4:1); ¹H NMR (300 MHz, Acetone-d₆): δ = 2.12 (s, 3H), 2.30 (s, 3H), 7.05 (d, 1H, *J* = 1.8 Hz), 7.31 (dd, 1H, *J* = 0.5, 1.8 Hz), 8.61 (s, 1H), 10.42 (s, 1H); ¹³C NMR (Acetone-d₆): δ = 11.1, 22.6, 112.3, 116.7 (2C), 120.1, 124.5,

128.1, 130.1, 133.9, 169.2; **GC-MS** (EI): m/z (%) 256 (43) [M⁺]; **HRMS** (EI): Calc for C₁₁H₁₀ON₂Cl₂: 256.01647; found: 256.01652; **FTIR** (ATR, cm⁻¹): 3273, 3154, 3094, 3066, 2958, 2926, 2871, 2778, 1636, 1563, 1539, 1483, 1369, 1288, 1255, 1034, 874, 863, 831, 686.

N-(2-Methyl-1H-indol-3-yl)acetamide (12)^[27] from arylhydrazine 1j and alkyne 2a

NHAC Yield: 172 mg (91%); white crystals; Mp 113-115 °C (from acetone/heptane) (lit. 156-157°C); $\mathbf{R_f} = 0.2$ (solvent ethyl acetate/heptane 4:1); ¹H NMR (300 MHz, DMSO-d_6): $\delta = 2.04$ (s, 3H), 2.22 (s, 3H), 6.92 (ddd, 1H), 6.99 (ddd, 1H), 7.23 (dd, 1H, $J \sim 8.3$ Hz), 7.25 (dd, 1H, $J \sim 8.4$ Hz), 9.17 (s, 1H), 10.82 (s, 1H); ¹³C NMR (DMSO-d_6): $\delta = 11.3$, 22.7, 110.3, 110.6, 117.3, 118.3, 120.2, 124.9, 129.5, 133.6, 168.5; GC-MS (EI): m/z (%) 188 (52) [M⁺]; HRMS (EI): Calc for C₁₁H₁₂ON₂: 188.09441; found: 188.094323; FTIR (ATR,

cm⁻¹): 3255, 3226, 3197, 3113, 3081, 3059, 2920, 2885, 1625, 1540, 1427, 1312, 1293, 1245, 1169, 1010, 740, 694, 668.

N-(1,2-Dimethyl-1H-indol-3-yl)acetamide (13) from arylhydrazine 1k and alkyne 2a



Yield: 111 mg (55%); white crystals; Mp 185 °C (from acetone/heptane); $\mathbf{R_f} = 0.26$ (solvent ethyl acetate/heptane 4:1); ¹H NMR (300 MHz, DMSO-d_6): $\delta = 2.05$ (s, 3H), 2.22 (s, 3H), 3.64 (s, 3H), 6.95 (m, 1H), 7.06 (m, 1H), 7.27 (d, 1H, J = 7.7 Hz), 7.36 (d, 1H, J = 8.2 Hz), 9.20 (s, 1H); ¹³C NMR (DMSO-d_6): $\delta = 9.9$, 22.7, 29.4, 109.0, 110.1,

117.4, 118.5, 120.3, 124.1, 131.3, 134.6, 168.7; **GC-MS** (EI): m/z (%) 202 (52) [M⁺]; **HRMS** (EI): Calc for C₁₂H₁₄ON₂: 202.11006; found: 202.10981; **FTIR** (ATR, cm⁻¹): 3230, 3112, 3032, 2914, 2833, 1649, 1525, 1472, 1370, 1334, 1284, 1196, 1010, 733.

<u>N-(5-Bromo-2-methyl-1*H*-indol-3-yl)benzamide (14) from arylhydrazine 1a and alkyne 2b</u>



Yield: 244 mg (74%); white crystals; Mp 230 °C (from acetone/heptane); $\mathbf{R_f} = 0.48$ (solvent ethyl acetate/heptane 2:1); ¹H NMR (300 MHz, DMSO-d_6): $\delta = 2.30$ (s, 3H), 7.13 (dd, 1H, J = 1.7, 8.5 Hz), 7.26 (d, 1H, J = 8.5 Hz), 7.45 (s, 1H), 7.54 (m, 3H), 8.04 (d, 2H, J = 7.9 Hz), 9.81 (s, 1H), 11.20 (s, 1H); ¹³C NMR (DMSO-d_6): $\delta = 11.4$, 109.9,

111.1, 112.7, 119.8, 122.6, 126.7, 127.7 (2C), 128.4 (2C), 131.4, 132.0, 132.3, 134.5, 165.6; **GC-MS** (EI, 70 eV): m/z (%) 328 (87) [M⁺], 330 (85) [M⁺]; **HRMS** (EI): Calc for $C_{16}H_{13}BrN_2O$: 328.02058 and 330.01853; found: 328.02040 and 330.01848; **FTIR** (ATR, cm⁻¹): 3429, 3306, 3056, 2965, 2924, 2868, 2710, 1614, 1506, 1469, 1295, 1274, 1243, 1177, 1116, 1066, 794, 718, 690.

<u>2-(5-Bromo-2-methyl-1*H*-indol-3-yl)isoindoline-1,3-dione (15) from arylhydrazine 1a and alkyne 2c</u>



Yield: 238 mg (67%); white crystals; Mp 249 °C (from acetone/heptane); $\mathbf{R}_{f} = 0.41$ (solvent ethyl acetate/heptane 1:1); ¹H NMR (300 MHz, Acetone-d₆): $\delta = 2.35$ (s, 3H), 7.20 (dd, 1H, J = 1.9, 8.6 Hz), 7.34 (dd, 1H, J = 0.5, 8.6 Hz), 7.56 (d, 1H, J = 1.9 Hz), 7.90 (m, 2H), 7.95 (m, 2H), 10.66 (s, 1H); ¹³C NMR (Acetone-d₆): $\delta = 11.1$, 104.9, 113.0, 113.3, 113.4, 120.5, 123.7 (2C), 124.3, 127.5, 127.6, 133.1, 133.7, 134.8 (2C), 135.5, 167.8; **GC-MS** (EI, 70 eV): m/z (%) 354 (100) [M⁺],

356 (97) [M⁺]; **HRMS** (EI): Calc for $C_{17}H_{11}BrN_2O_2$: 353.99984 and 355.99780; found: 353.99964 and 355.99701; **FTIR** (ATR, cm⁻¹): 3381, 3105, 3047, 3029, 2920, 1716, 1468, 1376, 1307, 1084, 1046, 881, 856, 802, 793, 714.

<u>2-(1,2-Dimethyl-1*H*-indol-3-yl)isoindoline-1,3-dione (16a) from arylhydrazine 1k and alkyne 2c</u>



Yield: 151 mg (52%); yellow crystals; Mp 236 °C (from acetone/heptane); $\mathbf{R_f} = 0.5$ (solvent ethyl acetate/heptane 1:1); ¹H NMR (300 MHz, Acetone-d_6): $\delta = 2.32$ (s, 3H), 3.79 (s, 3H), 7.01 (ddd, 1H, $J \sim 1.0, 7.2, 8.1$ Hz), 7.15 (ddd, 1H, $J \sim 1.3, 7.1, 8.3$ Hz), 7.31 (d, 1H, $J \sim 7.9$ Hz), 7.43 (d, 1H, $J \sim 8.2$ Hz), 7.92 (m, 2H), 7.96 (m, 2H); ¹³C NMR (Acetone-d_6): $\delta = 9.8, 29.8, 103.7, 108.1, 109.8, 117.8, 120.1, 121.6, 123.8 (2C), 125.2, 133.0 (2C), 134.9 (2C), 136.2, 168.0 (2C); GC-MS (EI, 70 eV): <math>m/z$ (%) 290 (100) [M⁺]; HRMS (EI): Calc for C₁₈H₁₄N₂O₂: 290.10498; found: 290.10502; FTIR (ATR, cm⁻¹): 3474, 3101, 3044,

3026, 2951, 2914, 2851, 1717, 1702, 1467, 1391, 1307, 1109, 1086, 879, 747, 715, 686, 644, 527.

<u>2-((1-Methyl-1*H*-indol-3-yl)methyl)isoindoline-1,3-dione (16b) from arylhydrazine 1k and alkyne 2c</u>



Yield: 55 mg (19%); white crystals; Mp 180-181 °C (from acetone/heptane); $\mathbf{R}_{f} = 0.6$ (solvent ethyl acetate/heptane 1:1); ¹H NMR (400 MHz, DMSO -d_6): $\delta = 3.72$ (s, 3H), 4.86 (s, 2H), 7.03 (ddd, 1H, $J \sim 0.9$, 7.2, 8.0 Hz), 7.13 (ddd, 1H, $J \sim 1.3$, 7.0, 8.1 Hz), 7.35 (s, 1H), 7.37 (ddd, 1H, $J \sim 9.1$ Hz), 7.67 (ddd, 1H, $J \sim 8.1$ Hz), 7.80 (m, 3H), 7.84 (m, 2H); ¹³C NMR (DMSO-d_6): $\delta = 32.3$, 32.4, 108.9, 109.8, 118.6, 119.0,

121.4, 123.1 (2C), 126.3, 129.4, 131.5 (2C), 134.5 (2C), 136.5, 167.7 (2C); **GC-MS** (EI, 70 eV): m/z (%) 290 (100) [M⁺]; **HRMS** (EI): Calc for C₁₈H₁₄N₂O₂: 290.10498; found: 290.10525; **FTIR** (ATR, cm⁻¹): 3453, 3101, 3058, 3028, 2938, 2883, 2833, 1706, 1464, 1422, 1392, 1325, 1305, 1099, 1064, 939, 750, 723, 710, 616, 524, 515, 428.

<u>N-(5-Bromo-2-methyl-1H-indol-3-yl)benzo[b]thiophene-3-sulfonamide (17) from</u> <u>arylhydrazine 1a and alkyne 2d</u>



Yield: 215 mg (51%); light yellow crystals; Mp 77-80 °C (from acetone/heptane); $\mathbf{R}_{f} = 0.47$ (solvent ethyl acetate/heptane 1:1); ¹H NMR (400 MHz, Acetone-d₆): $\delta = 2.06$ (s, 3H), 2.99 (bs, 1H), 6.75 (d, 1H, J = 1.9 Hz), 6.99 (dd, 1H, J = 2.0, 8.6 Hz), 7.14 (d, 1H, J = 8.5 Hz), 7.47 (m, 2H), 8.03 (s, 1H), 8.05 (m, 1H), 8.21 (m, 1H), 10.44 (s, 1H); ¹³C NMR (Acetone-d₆): $\delta = 10.4$, 108.5, 112.7, 112.9, 120.0, 123.5, 123.8, 124.0, 125.8, 126.0, 128.5, 128.8, 133.1, 134.9, 135.3, 136.4, 141.0; HRMS neg. (ESI): Calc for C₁₇H₁₃N₂O₂BrS₂: 418.95291 and 420.95085; found:

418.95311 and 420.95108; **HRMS pos.** (**ESI**): Calc for C₁₇H₁₃N₂O₂BrS₂Na: 442.9494 and 444.94735; found: 442.94926 and 444.94721; **FTIR** (ATR, cm⁻¹): 3322, 3260, 3102, 3062, 2922, 2853, 1582, 1455, 1424, 1311, 1284, 1142, 976, 865, 796, 755, 731, 707, 678.

N-(Prop-2-ynyl)benzo[b]thiophene-3-sulfonamide (2d)



To the solution of propargylamine (165 mg, 3 mmol) in CH_2Cl_2 (3 ml) and triethylamine (3 ml) was added benzo[b]thiophene-3-sulfonyl chloride (465.4 mg, 2 mmol) at 0°C under an argon atmosphere. After 30 min the reaction mixture was warmed to room temperature and stirring was continued for 2 h. After the reaction was complete (TLC control), the solvent was removed in vacuum and the solid rest was recrystallized.

Yield: 452 mg (90%); white crystals; Mp 95 °C (from CH₂Cl₂/heptane); $\mathbf{R}_{f} = 0.46$ (solvent ethyl acetate/heptane 1:1); ¹H NMR (300 MHz, CDCl₃): $\delta = 1.94$ (t, 1H, J = 2.5 Hz), 3.86 (dd, 1H, J = 2.5, 6.2 Hz), 5.10 (t, 1H, J = 2.5 Hz), 3.86 (dd, 1H, J = 2.5 Hz), 5.10 (t, 1H, J = 2.5 (t, 2Hz), 5.10 (t, 1H, J = 2.5 Hz), 5.10 (t, 1H, J = 2.5 (t, 2Hz), 5.10 (t, 1H, J = 2.5 (t, 2Hz), 5.10 (t, 1H, J = 2.5 (t, 2Hz), 5.10 (t, 1H, J = 2.5 (t, 2Hz), 5.10 (t

5.9 Hz), 7.48 (m, 2H), 7.90 (m, 1H), 8.19 (m, 1H), 8.29 (s, 1H); ¹³C NMR (CDCl₃): δ = 32.8, 72.7, 77.7, 122.9 (2C), 125.7, 125.8, 132.8, 133.6, 135.3, 140.3; GC-MS (EI, 70 eV): *m/z* (%) 251 (53) [M⁺]; HRMS (EI): Calc for C₁₁H₉NO₂S₂: 251.00692; found: 251.00715; FTIR (ATR, cm⁻¹): 3360, 3103, 3060, 2968, 1421, 1329, 1319, 1149, 1140, 1053, 973, 851, 812, 749, 720, 709.

<u>N-(5-Bromo-2-methyl-1H-indol-3-yl)acetamide (3)</u>



<u>N-(5-Fluoro-2-methyl-1H-indol-3-yl)acetamide (4)</u>



<u>N-(5-Chloro-2-methyl-1*H*-indol-3-yl)acetamide (5)</u>



N-(5-Iodo-2-methyl-1H-indol-3-yl)acetamide (6)



<u>N-(2-Methyl-5-(methylsulfonyl)-1H-indol-3-yl)acetamide (7)</u>



N-(5-Cyano-2-methyl-1H-indol-3-yl)acetamide (8)



<u>N-(5-Isopropyl-2-methyl-1*H*-indol-3-yl)acetamide (9)</u>



N-(5-Bromo-7-fluoro-2-methyl-1H-indol-3-yl)acetamide (10)



N-(5,7-Dichloro-2-methyl-1H-indol-3-yl)acetamide (11)



N-(2-Methyl-1H-indol-3-yl)acetamide (12)



N-(1,2-Dimethyl-1H-indol-3-yl)acetamide (13)



N-(5-Bromo-2-methyl-1H-indol-3-yl)benzamide (14)



2-(5-Bromo-2-methyl-1*H*-indol-3-yl)isoindoline-1,3-dione (15)



2-(1,2-Dimethyl-1*H*-indol-3-yl)isoindoline-1,3-dione (16a)



2-((1-Methyl-1*H*-indol-3-yl)methyl)isoindoline-1,3-dione (16b)



<u>N-(5-Bromo-2-methyl-1H-indol-3-yl)benzo[b]thiophene-3-sulfonamide (17)</u>



N-(Prop-2-ynyl)benzo[b]thiophene-3-sulfonamide (2d)



140 135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 40 ppm